Samsara BioCapital, LLC: KALARIS THERAPEUTICS INC (KLRS): Quarterly 13F Position History
As of Q1 2026, Samsara BioCapital, LLC reported 12,948,081 shares of KALARIS THERAPEUTICS INC (KLRS), worth $74.7M and representing 7.3% of its 13F equity book. The position first appeared in Q1 2025 and has been disclosed across 5 13F-HR filings in Pactolio's tracked window.
- 12,948,081Shares Held (Latest Filing)
- $74.7MReported Market Value (Latest Filing)
- 7.3%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$34.6MQuarter-over-Quarter Value Change
- 12,948,081Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 5 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 12,948,081 | 0 | — | $74.7M | 7.3% | $5.8 |
| Q4 2025 | 12,948,081 | +1,500,000 | +13.1% | $109.3M | 11.3% | $8.4 |
| Q3 2025 | 11,448,081 | 0 | — | $66.2M | 8.6% | $5.8 |
| Q2 2025 | 11,448,081 | 0 | — | $30.6M | 6.3% | $2.7 |
| Q1 2025 | 11,448,081 | — | — | $91.9M | 16.4% | $8.0 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Samsara BioCapital, LLC first disclose a KLRS position in 13F-HR filings?
Samsara BioCapital, LLC first reported KALARIS THERAPEUTICS INC (KLRS) on its 13F-HR filing for the period ending 2025-03-31 (Q1 2025). The position has appeared on 5 reported quarters within Pactolio's tracked window.
What was Samsara BioCapital, LLC's most recent quarter-over-quarter share-count change in KLRS?
Samsara BioCapital, LLC held the same 12,948,081 shares of KLRS between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Samsara BioCapital, LLC's cost basis in KLRS?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.